Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Recruiting 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Prostatic Neoplasms 34Prostatic Neoplasms, Castration-Resistant 3Metastatic Castration-resistant Prostate Cancer 2Metastatic Castration-Resistant Prostate Cancer 2Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Salivary Gland Neoplasms 1Prostate Cancer Metastatic Disease 1Prostate Adenocarcinoma 1Newly Diagnosed Oligometastatic Prostate Cancer 1Neoadjuvant Therapy 1Metastatic Hormone-sensitive Prostate Cancer 1Melanoma 1Disease 1Castration-resistant Prostate Cancer 1Castrate Sensitive Prostate Cancer 1Carcinoma, Small Cell 1Carcinoma, Non-Small-Cell Lung 1Anus Neoplasms 1

Interventions

enzalutamide 4abiraterone 2sapanisertib 1onvansertib 1inavolisib 1abemaciclib 1Prednisone 1Docetaxel 1Abiraterone Acetate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Metastatic Castration-Resistant Prostate Cancer × abiraterone × Clear all
NCT07287150 2026-05-06

InavoPC

Hoffmann-La Roche

Phase 2 Recruiting
100 enrolled
Genitourinary

Metastatic Castration-Resistant Prostate Cancer

NCT03414034 2024-11-07

Onvansertib in Combination With Abiraterone and Prednisone in Adult Patients With Metastatic Castration-Resistant Prostate Cancer

Cardiff Oncology

Phase 2 Completed
72 enrolled 21 charts
Genitourinary

Metastatic Castration-Resistant Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡